Table 4 Efficacy analysis in 36 patients.
Phase | Acute % (CI) | Delayed % (CI) | Overall % (CI) |
|---|---|---|---|
No vomiting | 100 (90–100) | 100 (90–100) | 100 (90–100) |
No nausea | 97.2 (86–100) | 61.1 (45–75) | 61.1 (45–75) |
No significant nausea | 100 (90–100) | 94.4 (82–98) | 94.4 (82–98) |
Complete response | 100 (90–100) | 86.1 (71–94) | 86.1 (71–94) |
Complete control | 100 (90–100) | 86.1 (71–94) | 86.1 (71–94) |
Total control | 97.2 (86–100) | 55.6 (40–70) | 55.6 (40–70) |
